Neumora (NASDAQ: NMRA) officer plans cashless sale of 134K shares

Rhea-AI Filing Summary

Neumora Therapeutics, Inc. (NMRA) received a Rule 144 notice from officer Daljit Singh Aurora covering a proposed sale of up to 134,452 shares of common stock. The shares are to be sold through Merrill Lynch on NASDAQ, in connection with the exercise of employee stock options, using a broker assisted cashless sale, with a stated aggregate market value of $203,583.59. As context, the notice lists 187,895,912 shares of Neumora common stock outstanding and discloses additional sales of Neumora common stock by the same person during the prior three months.

Key Figures

Shares to be sold: 134,452 shares of common stock Aggregate market value of shares to be sold: $203,583.59 Shares outstanding: 187,895,912 shares +5 more

8 metrics

Shares to be sold 134,452 shares of common stock Maximum number of Neumora Therapeutics, Inc. shares covered by the Rule 144 notice

Aggregate market value of shares to be sold $203,583.59 Value associated with the 134,452 NMRA shares listed in the securities information

Shares outstanding 187,895,912 shares Neumora Therapeutics, Inc. common stock outstanding as listed in the filing

Shares sold on 08/17/2026 146,706 shares Neumora Therapeutics, Inc. common stock sold by Daljit Singh Aurora during the past 3 months

Aggregate amount on 08/17/2026 $220,135.18 Aggregate dollar amount for 146,706 NMRA shares sold on 08/17/2026

Shares sold on 08/18/2026 69,149 shares Neumora Therapeutics, Inc. common stock sold by Daljit Singh Aurora on 08/18/2026

Aggregate amount on 08/18/2026 $109,621.88 Aggregate dollar amount for 69,149 NMRA shares sold on 08/18/2026

Shares sold on 08/19/2026 61,918 shares Neumora Therapeutics, Inc. common stock sold by Daljit Singh Aurora on 08/19/2026

Key Terms

Rule 144, broker assisted cashless sale, exercise of employee stock options

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

broker assisted cashless sale financial

"Broker assisted cashless sale"

exercise of employee stock options financial

"Exercise of employee stock options"

FAQ

What does the Form 144 filing disclose for Neumora Therapeutics, Inc. (NMRA)?

The filing discloses that officer Daljit Singh Aurora has filed a Rule 144 notice for a proposed sale of up to 134,452 shares of Neumora Therapeutics, Inc. common stock, to be executed through Merrill Lynch on NASDAQ in connection with an option exercise.

How many NMRA shares are covered by the planned Rule 144 sale?

The notice covers a proposed sale of up to 134,452 shares of Neumora Therapeutics, Inc. (NMRA) common stock. These shares are associated with the exercise of employee stock options and are to be sold via a broker assisted cashless sale.

What aggregate value is associated with the NMRA shares in this Form 144?

The Form 144 lists an aggregate market value of $203,583.59 for the 134,452 Neumora Therapeutics, Inc. (NMRA) common shares covered by the notice. This value is reported in the securities information section of the filing.

How many Neumora Therapeutics (NMRA) shares are reported as outstanding in the filing?

The filing reports that 187,895,912 shares of Neumora Therapeutics, Inc. (NMRA) common stock were outstanding, as shown in the securities information section. This figure is provided as context and is separate from the shares covered by the Rule 144 notice.

What recent NMRA stock sales by Daljit Singh Aurora are disclosed?

The filing discloses prior sales of Neumora Therapeutics, Inc. (NMRA) common stock by Daljit Singh Aurora over three days: 146,706 shares on 08/17/2026, 69,149 shares on 08/18/2026, and 61,918 shares on 08/19/2026, each with corresponding aggregate dollar amounts.

What is the stated reason and method for the NMRA share sale in this Form 144?

The shares are tied to the exercise of employee stock options in Neumora Therapeutics, Inc. (NMRA). The filing indicates a broker assisted cashless sale as the method of disposition, with Merrill Lynch listed as the broker.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/20/2026 - 04:23 PM Accepted by SEC EDGAR 08/20/2026 - 04:22 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001793971
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Neumora Therapeutics, Inc.
SEC File Number	001-41802
Address of Issuer	260 ARSENAL PLACE, SUITE 1 WATERTOWN MASSACHUSETTS 02472
Phone	(857) 760-0900
Name of Person for Whose Account the Securities are To Be Sold	Aurora Daljit Singh
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	134452	203583.59	187895912	08/20/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	08/20/2026	Exercise of employee stock options	Neumora Therapeutics, Inc.			134452	08/20/2026	Broker assisted cashless sale

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Daljit Singh Aurora 260 ARSENAL PLACE, SUITE 1 WATERTOWN MA 02472	Common Stock	08/17/2026	146706	220135.18
Daljit Singh Aurora 260 ARSENAL PLACE SUITE 1 WATERTOWN MA 02472	Common Stock	08/18/2026	69149	109621.88
Daljit Singh Aurora 260 ARSENAL PLACE SUITE 1 WATERTOWN MA 02472	Common Stock	08/19/2026	61918	101917.37

144: Remarks and Signature

Remarks
Date of Notice	08/20/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Daljit Singh Aurora
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)